BioMarin Announces Publication in New England Journal of Medicine of One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults with Severe Hemophilia A
/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced publication of results from the Phase 3 GENEr8-1 study of valoctocogene...
Debra Charlesworth Traci Mccarty Exchange Commission Biomarin Pharmaceutical Inc Data Monitoring Committee New England Journal
Source: prnewswire.com